Abstract: Increased levels of metalloproteinase (MMP)-9 have been shown in hypertensive patients. Lercanidipine is a calcium channel blocker with antioxidant actions. We examined whether lercanidipine produces antioxidant effects and reduces MMP-9 activity in hypertensive patients in a placebo-controlled, crossover, single-blinded design study including 18 healthy volunteers (control group), and 14 hypertensive patients without (N = 7) or with (N = 7) diabetes mellitus. Hypertensive patients were randomized to treatment with placebo (15 days) or lercanidipine 20 mg/d (15 days). Arterial blood pressure was evaluated with ambulatory blood pressure monitoring. Plasma thiobarbituric acid reactive species (TBA-RS) levels were measured to assess oxidative stress, and plasma MMP-2 and MMP-9 were assayed by gel zymography before and after treatment with placebo or lercanidipine. Plasma concentrations of tissue inhibitor of metalloproteinases (TIMP)-1 were measured by ELISA. Lercanidipine reduced mean arterial pressure by 7% in hypertensive patients without diabetes (P , 0.05), but not in hypertensive patients with diabetes. It significantly decreased plasma TBA-RS levels in hypertensive patients without and with diabetes (95% confidence interval [CI], 226 to 246%, P = 0.048, and 222 to 233%, P = 0.036, respectively). In addition, lercanidipine decreased activated MMP-9 in hypertensive patients without and with diabetes (95% CI, 219 to 247%, P = 0.047, and 280 to 296%, P = 0.010, respectively). No effects were seen on MMP-2. No significant differences or changes in plasma TIMP-1 concentrations were found. Therefore, we demonstrate for the first time that lercanidipine consistently decreased MMP-9 activity and reduced oxidative stress in hypertensive patients, thus suggesting a mechanism probably involved in the pleotropic actions of lercanidipine.
H ypertension is a major risk factor for the development of atherosclerosis and coronary artery disease. When hypertension and diabetes mellitus are combined, the cardiovascular risk increases to very high levels 1 and complex changes entailing accelerated vascular remodeling take place. 2 Lately, a group of zinc-dependent endopeptidases called matrix metalloproteinases (MMPs) has been implicated in the vascular remodeling underlying the pathogenesis of atherosclerosis. 3 MMPs have been classically recognized as a group of enzymes involved in both physiological and pathologic degradation of extracellular matrix components, and increased MMP expression and activity may result in inappropriate cardiovascular remodeling and premature coronary atherosclerosis. 3 Importantly, increased circulating levels of MMP-9 have been described in patients with hypertension 4, 5 and in type 2 diabetic patients. 6 In addition, a recent study showed that circulating levels of MMP-9 can predict mortality in patients with coronary artery disease. 7 Taken together, these findings are consistent with the notion that MMP-9 may play a role in the pathophysiology of the cardiovascular changes associated with hypertension and diabetes mellitus, and that circulating levels of MMP-9 may have prognostic value. 4, 7 Lercanidipine is a vasoselective dihydropyridine calcium channel blocker (CCB) used for the management of hypertension. 8 Besides reducing blood pressure, lercanidipine has pleotropic actions that may significantly contribute to the benefits that it produces in the therapy for hypertension. For example, lercanidipine produced significant antioxidant effects in patients with hypertension 9, 10 and in patients with combined hypertension and diabetes mellitus type 2. 11 Moreover, incubation of endothelial cells with lercanidipine significantly reduced oxidized-LDL-induced intracellular reactive oxygen species formation. 12 In addition, while the effects of CCB on MMP activity/expression are not clear, 13 it is possible that lercanidipine and other CCB with antioxidant effects reduce MMP activity/expression in patients with both hypertension and diabetes mellitus. This suggestion is supported by experimental evidence indicating that enhanced oxidative stress is a major factor modulating MMP-2 and MMP-9 expression/activity 14, 15 and that reactive oxygen species (ROS) are involved in vascular remodeling of hypertension via MMP activation. 16 In this study, we hypothesized that hypertension is associated with increased oxidative stress and plasma MMP-9 activity, and that treatment of hypertensive patients with lercanidipine would produce antioxidant effects and reduce plasma MMP-9 activity. Finally, we have also determined the plasma concentrations of tissue inhibitor of metalloproteinases (TIMP)-1 because TIMP-1 is a major regulator of MMP-9 activity. 14 
METHODS

Subjects
This study was approved by our institutional review committee and each subject provided written informed consent. We studied 18 normal healthy volunteers (control group), and 14 patients with mild to moderate arterial hypertension without (N = 7; Hyp group) or with (N = 7; Hyp + DM group) type 2 diabetes mellitus. Healthy volunteers were recruited from general public whereas hypertensive patients were recruited from our hospital hypertension clinic. All the subjects provided a complete health history and underwent a physical examination, and laboratory analysis to exclude individuals with evidence of severe or secondary hypertension, other concomitant cardiovascular diseases, respiratory, hepatic, renal, or hematological dysfunction.
Study Protocol
The study had a placebo-controlled, crossover, singleblinded design. All hypertensive subjects had their antihypertensive treatment changed to 25 mg of hydrochlorothiazide PO plus 5 mg of ramipril PO for a period of 15 days. Subjects with both hypertension and diabetes mellitus were on oral hypoglycemic therapy in addition to hydrochlorothiazide and ramipril. Hypertensive subjects with or without diabetes were randomized to add placebo or lercanidipine (Asta Medica, Brazil) 20 mg/d, for 15 days. Thereafter they were crossed over for a second period of 15 days of treatment with the same dose of lercanidipine or placebo. Normotensive healthy volunteers received no drugs.
Venous blood samples (10-15 mL) were collected into tubes containing EDTA at baseline and after both treatments for 15 days with lercanidipine or placebo. Healthy volunteers were sampled at the same time intervals as hypertensive patients. Plasma samples were stored at -70°C until assayed as described below.
Ambulatory Blood Pressure Monitoring
An ambulatory blood pressure monitoring (ABPM, SpaceLabs, Model 90207, USA) was used to measure 24 hours systolic, diastolic and mean arterial pressure (24-hour SBP and 24-hDBP, respectively) and heart rate (HR) before and after treatment with placebo or lercanidipine. The ABPM was pre-set to record blood pressure every 15 minutes during daytime, and every 30 minutes during night-time. We used average 24h-SBP and 24h-DBP values for the assessment of lercanidipine antihypertensive efficacy.
Measurement of Thiobarbituric Acid Reactive Species (TBA-RS) in Plasma
To assess oxidative stress, TBA-RS were determined in triplicate plasma samples as previously described. 17 
SDS-Polyacrylamide Gel Electrophoresis (PAGE) Gelatin Zymography of MMP-2 and MMP-9
To assess plasma MMP-2 and MMP-9 activities, 10 mL and 30 mL of each plasma sample were diluted in 190 mL and in 170 mL of sample buffer (2% SDS, 125 mM Tris-HCl; pH 6.8, 10% glycerol, and 0.001% bromophenol blue), respectively. Thereafter, 10 mL of each plasma solution were loaded in each gel lane and gelatin zymography of MMP-2 and MMP-9 was performed as previously described. [18] [19] [20] Gelatinolytic activities were assayed by densitometry using a Kodak Electrophoresis Documentation and Analysis System (EDAS) 290 (Kodak, Rochester, NY). The pro and active forms of MMP-2 and MMP-9 were identified as bands at 72 and 67 KDa, and at 92 and 87 KDa, respectively. Finally, the individuals who performed the assays were blinded to the treatment group.
Measurement of TIMP-1 Concentrations in Plasma
The plasma concentrations of TIMP-1 were measured using a commercially available (Amersham Biosciences UK Limited, Buckinghamshire, UK) enzyme-linked immunosorbent assay (ELISA), which is based on a 2-site ÔsandwichÕ format. The TIMP-1 assay recognizes both free TIMP-1 and TIMP-1 complexed with MMPs, and does not cross react with TIMP-2.
Statistical Analysis
The results are expressed as means 6 SEM. One-way analysis of variance followed by the Student-Newman-Keuls test was used to analyze differences among groups. The changes in 24h-SBP, 24h-DBP, TBA-RS, TIMP-1 and MMPs activities were analyzed using Student t test for paired data and Bonferroni correction. A probability value , 0.05 was considered the minimum level of statistical significance. Table 1 summarizes the basic characteristics of the study subjects. There were no significant differences in the age, body mass index, serum creatinine and hemoglobin concentrations among groups. Whereas hypertensive patients presented higher levels of total cholesterol, LDL, and triglycerides, blood pressure, and HR compared with normotensive control subjects (all P , 0.05), no significant differences were observed when patients with hypertension were compared with patients with hypertension and diabetes mellitus, except for higher hemoglobin A 1c levels in this last group of patients (P = 0.021). Figure 1 shows that whereas lercanidipine 20 mg significantly reduced 24 hours ambulatory average 24h-SBP and 24h-DBP in patients with hypertension (N = 7, P = 0.041), no effects were observed in patients with hypertension and diabetes mellitus (N = 7; P . 0.05; Fig. 1 ). In addition, no significant changes were seen in heart rate (data not shown). Figure 2 shows higher TBA-RS levels in hypertensive patients compared with normotensive controls (P , 0.05). In addition, treatment with lercanidipine significantly decreased plasma TBA-RS levels in both patients with hypertension (P = 0.048) and in patients with hypertension and diabetes mellitus (P = 0.036) (Fig. 2) .
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Plasma Activities of MMP-2 and MMP-9
Whereas the bands corresponding to pro-MMP-9, activated MMP-9, and pro-MMP-2 were identified in gelatin zymography, no band corresponding to active-MMP-2 was detected (Fig. 3) . Intra-assay and interassay coefficients of variation were less than 3.5%, and less than 9.0%, respectively. Figure 4 shows that patients with hypertension (with or without diabetes mellitus) have higher mean values of activated MMP-9 than normotensive healthy volunteers (P = 0.022).
Whereas no significant change in MMP-9 activity was seen in normotensive healthy volunteers sampled at the same time intervals as hypertensive patients (data not shown), treatment with lercanidipine significantly reduced the values of active MMP-9 in both sub-groups of patients with hypertension (P = 0.047 and P = 0.010 for Hyp group and Hyp+DM group, respectively). It should be noted that this lercanidipineinduced effect was observed in every single patient. In addition, whereas patients with hypertension and diabetes have higher pro-MMP-9 values than normotensive controls (P = 0.047), lercanidipine did not affect the circulating levels of pro-MMP-9 (P . 0.05).
Finally, whereas no significant differences were found in pro-MMP-2 values of hypertensive patients (both sub-groups) compared with normotensive controls, lercanidipine produced no significant decreases in pro-MMP-2 activities in hypertensive patients with or without diabetes mellitus (P . 0.05; Fig. 4 ). Figure 5 shows that whereas normotensive controls tended to have higher plasma concentrations of TIMP-1 compared with hypertensive patients (P = 0.101), treatment with lercanidipine produced no effects in both patients with hypertension and in patients with hypertension and diabetes mellitus (both P . 0.05; Fig. 5 ). 
TIMP-1 Concentrations in Plasma
DISCUSSION
In this study, we demonstrate for the first time that a short-term treatment with lercanidipine consistently decreased MMP-9 activity without affecting TIMP-1 concentrations in both patients with hypertension and in patients with hypertension and diabetes mellitus. The decrease in MMP-9 activity without significant changes in TIMP-1 (a major inhibitor of MMP-9) suggests that treatment with lercanidipine reduced net MMP-9 activity in both groups of patients. This lercanidipine-induced effect was associated with a significant reduction in oxidative stress in both groups of patients and may shed some light on the possible mechanisms involved in the pleotropic actions of this third-generation L-type CCB. Although the precise role of MMPs in the pathophysiology of hypertension is not known at present, several experimental studies have shown that hypertension is associated with abnormal MMP activity and disturbances of extracellular matrix accumulation in the cardiovascular system. 3, 22, 23 For example, increased transmural arterial pressure induced MMP-2 and MMP-9. 24 Moreover, vascular smooth muscle cells exposed to mechanical stretch were shown to induce ROS formation thereby increasing the expression and the release of MMP-2. 16 Whereas many laboratory experiments suggest that increased MMP-2 and MMP-9 activities play a role in hypertension, previous clinical studies have shown higher levels of MMP-9 4,5 and lower TIMP-1 25 concentrations in hypertensive patients compared with controls. Our present results are in line with these recent studies 4, 5 showing increased plasma MMP-9 activity in patients with hypertension. Importantly, the net level of MMP-9 activity depends on the relative concentrations of the active enzyme and its specific tissue inhibitor (TIMP-1). In the present study, we found that hypertensive patients presented higher MMP-9 activity and unchanged plasma concentrations of TIMP-1 when compared with normotensive controls, thus suggesting increased net MMP-9 activity in hypertensive that in normotensive subjects. While these present findings are supported by previous clinical studies, 4, 5 lower MMP-9 levels were reported in hypertensive patients compared with normotensive controls. 26 One possible explanation for this discrepancy is that MMP-9 levels were assessed by ELISA in that study. 26 Moreover, TIMP-1 concentrations were not measured in that study, thus precluding the analysis of net MMP-9 activity. 26 In the present study, we have used gel zymography, which is a powerful tool because it allows both the active and the latent forms of both MMP-2 and MMP-9 to be detected in concentrations as low as 1 nM. 27 In addition to significant methodological differences between studies, another explanation may be related to the instability of the MMP-9 measurement over time. 28 It has been shown that a sharp decrease in the plasma levels of MMP-9 occurs during the first 3 months of storage at -80°C. 28 Therefore, plasma MMP-9 levels should be determined as soon as possible after sampling, 28 and blood samples should be drawn from all groups of subjects at the same time.
Hypertensive patients with diabetes mellitus presented increased MMP-9 activity and lower TIMP-1 concentrations when compared with healthy controls in the present study. These findings are similar to those previously shown in patients with diabetes type 2 and treated hypertension, who had higher MMP-9 levels than healthy controls. 6 Indeed, elevated plasma concentrations of MMP-9 were reported in diabetic patients, and there is increasing evidence supporting the idea that increased MMP-9 expression is associated with the cardiovascular complications of diabetes. 29 Increased concentrations of ROS have been consistently shown in both animal models of hypertension and diabetes, and in clinical hypertension and diabetes. 30 In addition, it is now clear that enhanced oxidative stress is a major factor that modulates MMP-2 and MMP-9 expression/activity 14, 15 and that ROS are involved in vascular remodeling via MMP activation. 16 Therefore, antihypertensive drugs that could abrogate these mechanisms of disease progression as a consequence of their pleotropic effects may prove to be superior than other antihypertensive drugs that can simply lower blood pressure. Our results strongly suggest that lercanidipine can produce such beneficial pleotropic effects. We found that lercanidipine treatment decreased oxidative stress in both groups of hypertensive patients. These results support previous data showing antioxidant effects of lercanidipine in patients with hypertension 9, 10 and in patients with combined hypertension and diabetes mellitus type 2.
11 Besides producing antioxidant effects, our results show that lercanidipine treatment was associated with decreased values of active MMP-9 in both sub-groups of patients with hypertension. Taken together, these results suggest that the antioxidant effects of lercanidipine can attenuate the increased MMP-9 expression/activity in hypertensive patients with or without diabetes mellitus. In addition, our results show that lercanidipine treatment produced no significant reduction in MMP-2 activity in hypertensive patients with or without diabetes mellitus. Although other CCBs such as felodipine, lacidipine and amlodipine have also shown antioxidant effects, 13 and amlodipine decreased MMP-2 expression in rat cardiac fibroblast, 31 CCBs may produce differential pleotropic effects, and it remains to be determined whether these CCBs can affect MMP activity in hypertension and diabetes. Indeed, whereas the responses to CCBs are largely attributed to their primary mechanism of action, it is probable that their pleotropic actions contribute to their clinical effects. 13 Presently, it is not possible to choose which CCB produce the best pleotropic effects.
Some limitations of our study should be taken into consideration. Firstly, the relatively small number of hypertensive patients (N = 14) may have limited our conclusions. For example, lercanidipine treatment significantly reduced 24h-SBP and 24h-DBP in patients with hypertension. Conversely, no such effects were observed in hypertensive patients with diabetes mellitus. However, the present study was not designed to address the antihypertensive effect of lercanidipine, which has been previously demonstrated in hypertensive patients with diabetes. 32 Importantly, the main goal of the present study was to assess the effects of lercanidipine treatment on MMP-2 and MMP-9 activities in hypertensive patients, and lercanidipine treatment reduced the values of active MMP-9 activity in every single patient enrolled in the present study. Secondly, although our findings provide some evidence for the mechanisms involved in the pleotropic actions of lercanidipine, our results do not prove that lercanidipine treatment can protect against the vascular remodeling 3 and cardiac fibrosis 22 encountered in hypertensive patients. Moreover, we have not examined the effects of a chronic treatment with lercanidipine. In this regard, a previous study showed that 6 months of treatment with felodipine raised MMP-2 levels, whereas diltiazem produced no effects. 33 Thirdly, although detection of TBA-RS is sensitive for the measurement of oxidative stress, it is not specific. 34 It remains, however, one of the most widely used indicators of reactive oxygen species formation in vitro and in vivo. 34 Finally, we have examined the effects of lercanidipine treatment in hypertensive patients that were taking thiazide and ramipril. In addition, oral hypoglycemics have complex metabolic effects. Therefore we cannot exclude the possibility of a combination therapy effect.
In conclusion, our data show that lercanidipine treatment has antioxidant effects and decreases MMP-9 activity in patients with hypertension with our without diabetes mellitus. These findings may shed some light on the possible mechanisms involved in the pleotropic actions of this thirdgeneration L-type CCB. Further studies should be conducted to examine whether these effects translate into less cardiovascular remodeling and clinical events.
